These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 3873326)

  • 1. Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day.
    Lanza FL; Rack MF; Wagner GS; Balm TK
    Dig Dis Sci; 1985 Jun; 30(6):509-12. PubMed ID: 3873326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa.
    Lanza FL; Royer GL; Nelson RS
    N Engl J Med; 1980 Jul; 303(3):136-8. PubMed ID: 6966762
    [No Abstract]   [Full Text] [Related]  

  • 3. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis.
    Hawthorne AB; Mahida YR; Cole AT; Hawkey CJ
    Br J Clin Pharmacol; 1991 Jul; 32(1):77-83. PubMed ID: 1888645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salicylsalicylic acid causes less gastroduodenal mucosal damage than enteric-coated aspirin. An endoscopic comparison.
    Scheiman JM; Behler EM; Berardi RR; Elta GH
    Dig Dis Sci; 1989 Feb; 34(2):229-32. PubMed ID: 2914543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastric injury caused by low-dose aspirin therapy in consecutive Japanese patients: a prospective study.
    Fukuda S; Hosaka S; Ozawa N; Akita S; Kashima T; Kimura S; Akiyama J; Mizoue T
    Gen Thorac Cardiovasc Surg; 2012 May; 60(5):275-9. PubMed ID: 22453536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach.
    Hawkey CJ; Hawthorne AB; Hudson N; Cole AT; Mahida YR; Daneshmend TK
    Clin Sci (Lond); 1991 Oct; 81(4):565-73. PubMed ID: 1657506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?
    Cole AT; Hudson N; Liew LC; Murray FE; Hawkey CJ; Heptinstall S
    Aliment Pharmacol Ther; 1999 Feb; 13(2):187-93. PubMed ID: 10102949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin.
    Jaszewski R; Calzada R; Dhar R
    Dig Dis Sci; 1989 Sep; 34(9):1361-4. PubMed ID: 2766902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimization of gastric damage with enteric-coated aspirin granules compared to buffered aspirin.
    Anslow JA; Balm TK; Hooper JW; Szego P; Wagner GS
    Pharmacology; 1985; 30(1):40-4. PubMed ID: 3975255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
    Goldstein JL; Scheiman JM; Fort JG; Whellan DJ
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):121-6. PubMed ID: 27002280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study.
    Chowdhury A; Ganguly G; Chowdhury D; Santra A; Gupta JD; Roy T
    Indian J Gastroenterol; 2001; 20(6):227-9. PubMed ID: 11817775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of enteric coating of aspirin tablets on occult gastrointestinal blood loss.
    Howe GB; Champion GD; Corrigan AB; Hewson J; Haski A; Day RO; Paull PD; Graham GG
    Aust N Z J Med; 1977 Dec; 7(6):600-4. PubMed ID: 350214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies.
    Petroski D
    Am J Gastroenterol; 1986 Jan; 81(1):26-8. PubMed ID: 3942122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Enteric-coated aspirin does not reduce the risk of gastrointestinal side effects].
    Haastrup P; Jarbøl DE
    Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions.
    Dammann HG; Burkhardt F; Wolf N
    Aliment Pharmacol Ther; 1999 Aug; 13(8):1109-14. PubMed ID: 10468689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is enteric aspirin safer than regular aspirin?
    Johns Hopkins Med Lett Health After 50; 2013 Aug; 25(7):7. PubMed ID: 24386685
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of a new slow release aspirin ("slow aspirin") with plain aspirin in the treatment of rheumatoid disease.
    Clarke DN; Mowat NA; Brunt PW; Bain LS
    J Int Med Res; 1977; 5(4):270-5. PubMed ID: 881098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits.
    Lanza FL; Kochman RL; Geis GS; Rack EM; Deysach LG
    Am J Gastroenterol; 1991 Dec; 86(12):1743-8. PubMed ID: 1962619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.
    Kelly JP; Kaufman DW; Jurgelon JM; Sheehan J; Koff RS; Shapiro S
    Lancet; 1996 Nov; 348(9039):1413-6. PubMed ID: 8937281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of endoscopically assessed acute aspirin-induced gastric mucosal injury with cimetidine.
    Kimmey MB; Silverstein FE; Saunders DR; Chapman RC
    Dig Dis Sci; 1987 Aug; 32(8):851-6. PubMed ID: 3301232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.